Scientific Advisory Board
A world-class team of academic researchers and pharmaceutical development executives supports ArQule’s efforts in cancer therapeutics.
Alan D'Andrea, M.D. is the Fuller-American Cancer Society Professor of Radiation Oncology at Harvard Medical School. He is the Chief of the Division of Radiation and Cancer Biology at the Dana-Farber Cancer Institute. Dr. D'Andrea's laboratory studies the molecular basis of DNA repair and the DNA damage response and has made fundamental discoveries in the FA/BRCA repair pathway. Dr. D'Andrea has a longstanding interest in the molecular pathogenesis of leukemia and breast/ovarian cancers.
Werner Cautreels, Ph.D. was a director of ArQule from September 1999 until April 2006. He has over 20 years of experience in the healthcare industry. Since May 1998, Dr. Cautreels has been the Global Head of Research and Development of Solvay Pharmaceuticals. Prior to that time, Dr. Cautreels served as Senior Vice President of Research and Development at Nycomed Amersham Ltd., held two senior management positions at Sterling Winthrop and served as Vice President of Scientific Affairs at Sanofi Pharmaceuticals, where he conducted clinical trials in various therapeutic areas and researched licensing opportunities. Dr. Cautreels received his Ph.D. in Chemistry from University of Antwerp, Belgium.
Gerard I. Evan, Ph.D. is the Gerson and Barbara Bass Baker Distinguished Professor of Cancer Biology at the University of California, San Francisco. Dr. Evan has made fundamental contributions to the understanding of how activation of the oncogene c-myc contributes to apoptosis and carcinogenesis. He is widely considered a pioneering thinker and world authority on apoptosis in cancer biology.
Alfred L. Goldberg, Ph.D. is a Professor of Cell Biology at Harvard Medical School. He is a world’s leading authority on cell protein turnover. Dr. Goldberg elucidated the structure and function of the proteasome and has made numerous seminal discoveries related to how cells regulate protein turnover. Recent work has included study of mechanisms by which the 26S proteasome degrades ubiquitin-conjugated proteins and the importance of molecular chaperones in folding and degrading cellular proteins. In addition, Dr. Goldberg has made an important contribution to the discovery of Velcade.
William G. Kaelin, Jr., M.D. is a Professor of Medicine and a Clinical Oncologist at the Dana-Farber Cancer Institute and Harvard Medical School and is a Howard Hughes Medical Institute investigator. His research has elucidated fundamental mechanisms of tumor suppressor genes, including pathogenesis of enhanced incidence of cancer in von Hippel Lindau Syndrome, a genetic disease that can be used as a model of cancer pathogenesis generally. His laboratory has discovered genetic control elements, intracellular pathways and a novel enzyme that contributes to cancer formation.
Arthur B. Pardee, Ph.D. is Professor of Biological Chemistry and Molecular Pharmacology Emeritus at the Dana-Farber Cancer Institute and Harvard Medical School. A scientist of international stature, Dr. Pardee is a world-recognized authority on the cell cycle and regulations. He has made numerous seminal discoveries related to the cell cycle, including discovery of the restriction (“R”) cellular checkpoint in the G1 phase of the cell cycle, invention of differential display, allosteric regulation, feedback inhibition and transcription regulation. Dr. Pardee is a member of the National Academy of Sciences and the recipient of numerous national and international scientific awards.
Daniel D. Von Hoff, M.D., is Professor of Medicine, Molecular and Cellular Biology and Pathology, and Director of the Arizona Health Sciences Center’s Cancer Therapeutics Program at The University of Arizona and Director of Translational Research at the Translational Research Institute (Tgen). He is also Chief Scientific Officer for US Oncology Research. Dr. Von Hoff is developing molecularly targeted anticancer therapies, with particular concentration in the area of pancreatic cancer. He and his colleagues were involved in the development of mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine and CPT-11 and multiple other agents. His laboratory specializes in in-vitro drug sensitivity testing to individualize patient treatment, gene amplification and targeting telomere maintenance mechanisms. He is the author of over 503 papers, 126 book chapters and 843 abstracts. Dr. Von Hoff is past president of the American Association for Cancer Research, a fellow of the American College of Physicians and a member and past board member of the American Society of Clinical Oncology. He is associated in various capacities with many prominent publications, as founder, editor or co-editor, including “Investigational New Drugs- The Journal of New Anti-Cancer Agents,” “Clinical Cancer Research,” and “Molecular Cancer Therapeutics.”
Robert A. Weinberg, Ph.D. is the Daniel K. Ludwig and American Cancer Society Professor for Cancer Research at the Whitehead Institute, Massachusetts Institute of Technology. He is a member of the National Academy of Sciences and a winner of the 1997 National Medal of Science. In 1980, his laboratory identified the first human oncogene, ras. In 1986, he and his colleagues isolated the first tumor suppressor gene, the retinoblastoma (Rb) gene. These achievements revolutionized the way scientists think about the origins of cancer and paved the way for powerful new technologies in cancer diagnosis and treatment.